(Total Views: 618)
Posted On: 07/29/2020 11:49:44 AM
Post# of 153904
Re: Riztheinvestor #45655
I agree. Nearly every drug has a proper time, dose and patient profile for which it is indicated.
Leronlimab may be singularly unique, perhaps in the history of medicine. (Sorry for the hyperbole. Physicians and historians feel free to set me straight).
Lenzilumab I believe will still have a place. I owned shares as it appears effective for mitigating negative effects of CAR-T therapy. I sold my stake in humanigen and Fate therapeutics (CAR-T therapies) to buy more Cytodyn.
I am unable to find a way that leronlimab is not at most of what we believe it to be.
I expect, as expharmer just noted, that tomorrow should be our day.
28 hours, 12 minutes to go.
Leronlimab may be singularly unique, perhaps in the history of medicine. (Sorry for the hyperbole. Physicians and historians feel free to set me straight).
Lenzilumab I believe will still have a place. I owned shares as it appears effective for mitigating negative effects of CAR-T therapy. I sold my stake in humanigen and Fate therapeutics (CAR-T therapies) to buy more Cytodyn.
I am unable to find a way that leronlimab is not at most of what we believe it to be.
I expect, as expharmer just noted, that tomorrow should be our day.
28 hours, 12 minutes to go.
(2)
(0)
